Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals

Raf Winand, Kristof Theys, Mónica Eusébio, Jan Aerts, Ricardo J. Camacho, Perpetua Gomes, Marc A. Suchard, Anne Mieke Vandamme, Ana B. Abecasis

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

Objectives: Surveillance drug resistance mutations (SDRMs) in drug-naive patients are typically used to survey HIV-1-transmitted drug resistance (TDR). We test here how SDRMs in patients failing treatment, the original source of TDR, contribute to assessing TDR, transmissibility and transmission source of SDRMs. Design: This is a retrospective observational study analyzing a Portuguese cohort of HIV-1-infected patients. Methods: The prevalence of SDRMs to protease inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) in drug-naive and treatment-failing patients was measured for 3554 HIV-1 subtype B patients. Transmission ratio (prevalence in drug-naive/prevalence in treatment-failing patients), average viral load and robust linear regression with outlier detection (prevalence in drug-naive versus in treatment-failing patients) were analyzed and used to interpret transmissibility. Results: Prevalence of SDRMs in drug-naive and treatment-failing patients were linearly correlated, but some SDRMs were classified as outliers-above (PRO: D30N, N88D/S, L90M, RT: G190A/S/E) or below (RT: M184I/V) expectations. The normalized regression slope was 0.073 for protease inhibitors, 0.084 for NRTIs and 0.116 for NNRTIs. Differences between SDRMs transmission ratios were not associated with differences in viral loads. Conclusion: The significant linear correlation between prevalence of SDRMs in drug-naive and in treatment-failing patients indicates that the prevalence in treatment-failing patients can be useful to predict levels of TDR. The slope is a cohort-dependent estimate of rate of TDR per drug class and outlier detection reveals comparative persistence of SDRMs. Outlier SDRMs with higher transmissibility are more persistent and more likely to have been acquired from drug-naive patients. Those with lower transmissibility have faster reversion dynamics after transmission and are associated with acquisition from treatment-failing patients.

Original languageEnglish
Pages (from-to)2045-2052
Number of pages8
JournalAIDS
Volume29
Issue number15
DOIs
Publication statusPublished - 24 Sep 2015

Keywords

  • antiretroviral therapy
  • HIV drug resistance
  • mutation
  • protease inhibitors
  • reverse transcriptase inhibitors
  • transmission

UN Sustainable Development Goals (SDGs)

  • SDG 3 - Good Health and Well-Being

Fingerprint Dive into the research topics of 'Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals'. Together they form a unique fingerprint.

Cite this